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Photodynamic therapy (PDT) is a recently approved
treatment modality that involves the sequential
administration of a photosensitizer or its precursor
and light to generate singlet oxygen for treating
diseased tissue. The use of topical aminolevulinic
acid (ALA) and blue light for nonhypertrophic acti-
nic keratoses currently represents the only approved
dermatologic application for PDT in the U.S.A.
ALA is a photosensitizer precursor that is metabo-
lized by cells into protoporphyrin IX (PpIX), which
can be subsequently activated by visible light. PDT
with topical ALA has been shown to improve psoria-
sis, but post-treatment hyperpigmentation as well as
inconsistent clinical responses despite repeated PDT
sessions have limited the development of this treat-
ment approach for psoriasis. Furthermore the use of
topical PDT photosensitizers becomes somewhat
impractical for treating larger body surface areas in
patients with extensive psoriasis. We have recently
shown that oral administration of ALA induces pref-
erential accumulation of PpIX in psoriatic plaques.
The objectives of this study were to evaluate the
effects of PDT with blue light on psoriatic plaques
after systemic ALA administration as well as to
determine whether systemic ALA±PDT induces
apoptosis in lesional T lymphocytes. It has been sug-
gested that induction of apoptosis in lesional T lym-
phocytes may be indicative of longer remission time
following treatment of psoriasis. J Invest Dermatol
119:77±83, 2002
MATERIALS AND METHODS
Patients This protocol involving human subjects was approved by the
University of Montreal Hospital Center Ethics Committee, and informed
consent was obtained from each patient before any procedures were
performed. Three groups of four patients received a single oral ALA dose
of either 5, 10, or 15 mg per kg. ALA in powder form was provided by
DUSA Pharmaceuticals (Valhalla, NY) and mixed with orange juice
immediately before administration. Patients were all asked to eat
breakfast before coming to the clinic on the day of ALA administration.
Baseline laboratory evaluation included complete blood count, aspartate
amino transaminase (AST), alanine amino transaminase (ALT), alkaline
phosphatase (AP), lactate dehydrogenase (LDH), g-glutamyl transferase
(GGT), bilirubin, creatinine, urea, and urinalysis; AST, ALT, AP, GGT,
LDH, and bilirubin were repeated 24 h and 72 h after ALA
administration. On the day of ALA administration patients were kept
under subdued lighting at the dermatology clinic for the entire day.
PDT session and psoriasis evaluation For each patient a total of 15
1.5 3 1.5 cm square areas of psoriatic skin within three different plaques
on the limbs were selected for PDT and exposed to blue light at 1, 3, or
6 h after ALA administration. A blue ¯uorescent lamp (Blue-U, DUSA
Pharmaceuticals) at irradiances of 9±11 mW per cm2 was used for light
exposure. The maximal output of this source is at 417 nm with a full-
width half-maximum of 30 nm. The irradiance was measured each
morning with an International Light IL 1700 radiometer (Newburyport,
MA) equipped with a SED 240 detector, a UVB-1 ®lter, and a ``Wide
Eye'' Diffuser (W). The variation in irradiance according to differences
in the size of limbs from patient to patient was less than 10%. The
measured irradiance was multiplied by a factor of 1.65 following
comparison of the International Light radiometer against a UDT S370
radiometer (Graseby Optronics, Orlando, FL). Five squares within each
plaque were exposed to the following light ¯uences: 1, 3, 6, 12, or 20 J
per cm2 for patients who received 5 or 10 mg per kg and 1, 2, 4, 8, or
10 J per cm2 for patients who received 15 mg per kg. Psoriasis severity
was assessed separately at each treatment site at baseline and at days 1, 3,
7, and 28 following PDT according to the visible degree of erythema,
scaling, and thickness. Each of these features was evaluated on a scale of
0 (absence) to 4 (severe) and then added together to give the overall
psoriasis severity score, which had a maximum possible score of 12.
In vivo ¯uorescence spectroscopy PpIX ¯uorescence in psoriatic and
normal skin was monitored in vivo with a spectro¯uorometer equipped
with a xenon lamp and a double monochromator (Skin Skan, SPEX
Instruments, Edison, NJ). Fluorescence excitation was set at 407 nm and
emission intensity at 635 nm was serially measured at baseline and after
ALA administration for up to 24 h. These parameters were kept constant
for every patient. In addition emission spectra were also speci®cally
recorded before ALA administration as well as at 1, 3, and 6 h before
and immediately after light exposure on the squares that were exposed to
the lowest and highest ¯uence. For all emission spectra, PpIX
¯uorescence before and after light exposure was evaluated by measuring
the area under the emission spectra between 620 and 650 nm after
subtraction of the auto¯uorescence background.
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Quantitative ¯uorescence microscopy Skin biopsies of psoriatic skin
unexposed to blue light were taken before and at 1, 3, and 6 h after
ALA administration. These biopsies were embedded in Frozen Section
Medium (Stephens Scienti®c, Riverdale, NJ) and snap frozen in liquid
nitrogen. Sections of 10 mm thickness from each frozen sample were cut
with a cryostat, taking great care to minimize exposure of the sections to
light in order to minimize PpIX photobleaching. Fluorescence images
were generated with a Nikon Optiphot-2 ¯uorescence microscope
equipped with a thermoelectrically cooled CCD camera (Model
Figure 1. Oral administration of ALA at 10 and 15 mg per kg
induces preferential accumulation of PpIX in psoriatic plaques
compared to normal skin. PpIX levels were measured in normal and
psoriatic skin with in vivo ¯uorescence spectroscopy at different times
after administration of 5 mg per kg (a), 10 mg per kg (b), or 15 mg per
kg (c) of ALA. Bars: SD; n = 4.
Figure 2. PDT with 20 J per cm2 3 h after administration of
10 mg per kg of ALA induces erythema on exposed psoriatic
skin. (a) Before light exposure. (b) 24 h after light exposure erythema
(arrow) is present on the area exposed to 20 J per cm2. (c) 4 wk after
PDT improvement is present on the area exposed to 20 J per cm2
(arrow).
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DC330E, Dage-MTI, Michigan City, IN) connected to a PC computer.
The sensitivity settings on the camera were identical for each slide. The
integration time was 1 s. For ¯uorescence recording, a 480 nm short pass
(480DF60) excitation ®lter and a 635 6 10 nm bandpass (635DF55)
emission ®lter were used (Harvard Apparatus, Montreal, Canada). After
¯uorescence imaging, the slides were stained with toluidine blue and a
standard light microscope image of the same area was captured without
moving the microscope stage. All images were analyzed with Clemex
vision software (Version 3.0.023, Longueuil, Quebec, Canada). Using
this software, the stratum corneum and the rest of the epidermis were
delineated on the toluidine blue images, which were then superimposed
onto the ¯uorescence images for quantifying ¯uorescence intensity. The
average ¯uorescence intensity per pixel was calculated for the stratum
corneum and the rest of the epidermis.
Detection of apoptosis in lesional lymphocytes by double
sequential staining Twenty-four hours after ALA administration
4 mm skin biopsies were taken from one psoriatic square of each plaque
exposed to light as well as from an unexposed plaque. For each PDT-
treated plaque the biopsy was performed on the psoriatic square exposed
to the highest ¯uence that did not exhibit erythema. For patients treated
with 5 mg per kg all biopsies were from the squares exposed to 20 J per
cm2. For patients treated with 10 mg per kg all biopsies were performed
on squares exposed to 20 J per cm2 except three biopsies performed on
plaques exposed at 3 h after ALA administration that were from squares
exposed to 12 J per cm2. For patients treated with 15 mg per kg all
biopsies were from squares exposed to 10 J per cm2 except two from the
same patient that were performed on squares exposed to 8 J per cm2 for
plaques exposed at 3 and 6 h after ALA administration. After formalin
®xation and paraf®n embedding, sections were cut from each specimen.
Tissue sections where deparaf®nized, rehydrated in phosphate-buffered
saline (PBS), and then processed to detect apoptotic cells with the
TUNEL technique using the ApopTag Fluorescein in situ Apoptosis
Detection Kit (Intergen Compagny, Purchase, NY). Fluorescence images
demonstrating apoptotic cells were acquired with the Nikon Optiphot-2
¯uorescence microscope and recorded with the Clemex Vision Software
as previously described. The same tissue sections were then left overnight
at 4°C in their mounting medium, following which they were washed
in PBS and processed for anti-CD3 immunohistochemistry the next day.
Brie¯y, after blocking with the avidin/biotin blocking kit (Vector
Laboratories, Burlingame, CA) the sections where incubated for 1 h at
room temperature with a polyclonal rabbit antihuman CD3 antibody at a
dilution of 1:150 (Dako Diagnostic Canada, Mississauga, Ontario,
Canada). After three washes in PBS, tissue sections were incubated for
30 min at room temperature with a biotin-conjugated goat antirabbit
antibody diluted at 1:200 in 5% normal goat serum in PBS. Sections
were washed in PBS and signal ampli®cation and visualization were
carried out using an avidin/biotin/peroxidase complex and
diaminobenzidine (Vector Laboratories). Slides were dehydrated in
ethanol and xylene and mounted in VectaMount. Using the recorded
image of the TUNEL technique a corresponding image of the same area
was recorded after anti-CD3 immunohistochemistry. The number of
TUNEL + positive CD3 lymphocytes per ®eld was counted.
Statistical analysis A one-way ANOVA for repeated measures was
used for statistical analysis. A Bonferroni correction was applied when
multiple comparisons were performed.
RESULTS
Oral ALA induces preferential accumulation of PpIX in
psoriatic skin Following oral administration of ALA an emission
spectrum typical of PpIX was observed on psoriatic plaques of
patients who received 10 and 15 mg per kg. PpIX ¯uorescence
increased rapidly and signi®cantly over baseline in psoriatic skin
after administration of 10 mg per kg (p = 0.002) and 15 mg per kg
(p < 0.001) of ALA to reach a maximum at about 2±2.5 h (Fig 1).
PpIX ¯uorescence intensity did not increase signi®cantly after
administration of 5 mg per kg of ALA. PpIX ¯uorescence intensity
also increased slightly in normal skin after administration of ALA at
10 mg per kg (p = 0.01) and 15 mg per kg (p = 0.005) (Fig 1).
PDT with oral ALA and blue light induces mild erythema
followed by improvement within psoriatic plaques Two
patients who received 10 mg per kg developed mild erythema on
the face 24 h after PDT. Despite clear instructions to avoid sunlight
for the ®rst 2 d after ALA administration these two patients
sustained direct sun exposure for about 5 min after leaving the
clinic on the day of ALA administration. Blue light exposure was
well tolerated by all patients. Only one patient who received 15 mg
per kg complained of a mild but tolerable burning sensation during
light exposure. Increased erythema compared to nonexposed
psoriatic skin was observed in one patient treated with 15 mg per
kg followed by 10 J per cm2 of blue light at 3 and 6 h. Increased
erythema was also noted on psoriatic skin for three patients treated
with 10 mg per kg followed by exposure to 20 J per cm2 of blue
light 3 h later (Fig 2).
Erythema was not observed on psoriatic skin of patients who
received 5 mg per kg. Changes in plaque severity score were not
statistically signi®cant for patients who received 5 mg per kg and
10 mg per kg (Fig 3).
The best clinical improvement, however (Fig 2), was seen in a
patient who received 10 mg per kg. Individual clinical improve-
Figure 3. PDT after oral administration of
ALA decreases psoriatic plaque severity.
Plaque severity decreased following PDT on
1.5 3 1.5 cm areas of psoriatic skin after
administration of 15 mg per kg of ALA.
Improvement was not signi®cant for patients who
received 5 mg per kg or 10 mg per kg. Plaque
severity scores are given for 1 (gray), 6 (white), and
20 J per cm2 (black) for patients who received
5 mg and 10 mg per kg and 1 (gray), 4 (white),
and 10 J per cm2 (black) for patients who received
15 mg per kg. Plaques were exposed to blue light
at either 1 h, 3 h, or 6 h after ALA
administration. Bars: SD; n = 4.
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ment was not as marked for patients treated with 15 mg per kg. For
patients treated with 15 mg per kg the maximum improvement was
noted for psoriatic skin exposed to 10 J per cm2 of blue light 3 h
after ALA administration with a 42% improvement in plaque
severity compared to baseline (p < 0.001) (Fig 3).
PDT at the highest ¯uence induces photobleaching of
PpIX Immediately after blue light exposure the red emission
peak of PpIX intensity decreased in intensity to a level at which it
was not detectable for most patients (Fig 4).
Immediately after PDT performed at 3 h at the highest ¯uence,
PpIX ¯uorescence intensity decreased by 100%, 97%, and 88% for
patients who received 5, 10, and 15 mg per kg, respectively
(Fig 5). This was statistically signi®cant (p < 0.02) for all three ALA
doses.
Epidermal PpIX accumulation in psoriatic skin is maximal 3
h after administration of ALA Following administration of
ALA at 10 and 15 mg per kg an increase in red ¯uorescence was
mostly present in the epidermis (Fig 6).
A granular ¯uorescence was also observed in the dermis at 6 h
but the resolution of the un®xed sections was not suf®cient to
verify if it originated from immunocytes (Fig 6d). PpIX micro-
scope ¯uorescence intensity did not increase signi®cantly in the
stratum corneum or the epidermis following oral administration of
ALA at 5 mg per kg (Fig 7).
Following 10 mg per kg of ALA PpIX intensity increased
signi®cantly in the epidermis (p = 0.03) to reach a maximum at 3 h,
Figure 4. PDT with blue light after oral administration of ALA
induces photobleaching of PpIX. The emission spectrum from 550
to 675 nm was collected before (a) and after (b) irradiation of psoriatic
skin with 407 nm light. There is a decrease in the 635 nm PpIX peak
after blue light exposure.
Figure 5. PDT at the highest ¯uence induces almost complete
photobleaching of PpIX. PpIX levels were measured with in vivo
¯uorescence spectroscopy before and after PDT with 20 J per cm2 for
patients who received 5 mg per kg and 10 mg per kg, and after 10 J per
cm2 for patients who received 15 mg per kg. More than 85%
photobleaching of PpIX was observed at all three time points for all
ALA doses. A single emission spectrum was recorded from four patients
for each time point. Bars: SD.
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whereas the levels in the stratum corneum did not demonstrate
signi®cant changes (Fig 7). PpIX ¯uorescence intensity increased
by up to 2-fold in the epidermis after administration of 15 mg per
kg of ALA to reach a maximum at 3 h (p = 0.005) (Fig 7). PpIX
intensity also increased in the stratum corneum at 1 h (p = 0.03)
after ALA at 15 mg per kg (Fig 7).
PDT with oral ALA induces apoptosis in lesional CD3+
lymphocytes TUNEL+ and CD3+ cells were seen in the
dermis of psoriatic plaques of patients treated with ALA±PDT
(Fig 8).
The number of TUNEL+ and CD3+ cells per ®eld in the
dermis did not differ signi®cantly from baseline for patients treated
with 5 mg per kg or 15 mg per kg of ALA (Fig 9a).
For patients treated with 10 mg per kg of ALA there was a
signi®cant (p < 0.001) increase in the number of TUNEL+ and
CD3+ cells per ®eld in plaques exposed to light 3 h after ALA
administration compared to an unexposed plaque (Fig 9a). The
total number of TUNEL+ cells per ®eld in the epidermis was
increased after ALA±PDT with 10 mg per kg (p = 0.003) and
15 mg per kg (p = 0.005) (Fig 9b). This was signi®cant at 1 and 6 h
after PDT for 15 mg per kg as well as 3 h for 10 mg per kg. The
total number of TUNEL+ cells did not increase for patients treated
with 5 mg per kg.
DISCUSSION
In this study we showed that blue light exposure of psoriatic
plaques after oral administration of ALA induces apoptosis in
lesional T lymphocytes under suberythemogenic conditions. T
lymphocytes play a central role in the pathogenesis of psoriasis as
suggested by clinical improvements reported following treatment
with cyclosporine, interleukin-2±diphtheria toxin fusion protein
(Gottlieb et al, 1995), anti-CD4 (Rizova et al, 1994), and anti-
tumor necrosis factor a (Oh et al, 2000) monoclonal antibodies.
Induction of apoptosis in lesional T lymphocytes has also been
reported with other therapeutic modalities for psoriasis such as
ultraviolet B (UVB) phototherapy and psoralen plus UVA (PUVA)
therapy (Krueger et al, 1995; Coven et al, 1999). PUVA therapy for
example induces apoptosis in lymphocytes and has been associated
with one of the longest periods of remission of the existing
therapeutic modalities for psoriasis (Koo and Lebwohl, 1999). In a
previous study we failed to detect signi®cant PpIX accumulation in
resting circulating CD4 and CD8 T lymphocytes (Bissonnette and
Haishan, 2001). Activated T lymphocytes are more sensitive to
ALA±PDT-induced apoptosis in vitro, however, than their resting
counterpart (Rittenhouse-Diakun et al, 1995). Activated T
lymphocytes expressing CD25 are present in psoriatic skin and
might therefore be sensitive to ALA±PDT (Gottlieb, 1997). In this
study a signi®cant increase in apoptotic CD3+ lymphocytes was
only observed after ALA±PDT for patients treated with 10 mg per
kg. This could be related to a higher photosensitizer±light
combination and therefore a more important PDT effect in
patients with 10 mg per kg. Patients treated with 10 mg per kg
received as much as 20 J per cm2 of blue light compared to 10 J per
cm2 for patients who received 15 mg per kg. Because of the
relatively low penetration of blue light combined with light
scattering from psoriatic scales it is possible that at 10 J per cm2 not
enough blue light reached the dermis to induce apoptosis in T
lymphocytes. Clinically this resulted in an increase in erythema on
the exposed plaques for three out of four patients treated with
10 mg per kg as opposed to none treated with 5 mg per kg and
only one out of four treated with 15 mg per kg (light ¯uences were
lower at that higher ALA dose). The number of CD3+ TUNEL+
cells in the epidermis was too low to allow comparison of apoptosis
in T lymphocytes from unexposed and exposed plaques. In addition
the use of the TUNEL assay in psoriatic epidermis is more dif®cult
as it is associated with a higher level of false positive because of the
high number of actively dividing keratinocytes (Wrone-Smith et al,
1997). Nonetheless we observed an increase in the total number of
TUNEL+ cells in the epidermis after PDT with 10 and 15 mg per
kg. These cells could be apoptotic keratinocytes and/or T
lymphocytes.
The overall tolerability of systemic ALA±PDT was excellent. In
contrast to topical ALA±PDT for the treatment of psoriasis, which
can be quite painful (Robinson et al, 1999), patients did not
complain of pain during light exposure. Oral ALA at 30±60 mg per
kg has been associated with a high incidence of nausea, vomiting, as
well as decreased blood pressure (Regula et al, 1995; Rick et al,
1997; Webber et al, 1997). In this study only one patient who
received 15 mg per kg experienced nausea, suggesting that lower
ALA doses may be better tolerated for the treatment of psoriasis.
Erythema and mild edema were the only signs observed on some of
the exposed psoriatic skin areas after PDT; in all cases this was
asymptomatic, and the appearance of psoriatic skin returned to
baseline within 3 d after light exposure.
Clinical improvement as well as induction of apoptosis in T
lymphocytes were thus observed without crusting and/or necrosis,
which is often present after PDT for the treatment of skin tumors.
Nonspeci®c photosensitivity has been reported in patients treated
with ALA doses of 30±60 mg per kg (Regula et al, 1995; Sibille et
al, 1995). Facial erythema 24 h after administration of 30 mg per kg
of ALA has also been observed even with exposure limited to
ambient lighting (Bissonnette and Haishan, 2001). This was not
observed in this study with the lower ALA doses administered.
Slight facial erythema was observed in two patients, however, who
were not compliant with sun avoidance measures, suggesting that
even at 10 mg per kg patients need to avoid sunlight, especially in
the ®rst 24 h. Further studies on facial accumulation of PpIX will
need to be performed in order to fully evaluate the duration of
photosensitivity.
PpIX accumulation in psoriatic skin was observed using in vivo
¯uorescence spectroscopy for patients who received 10 and 15 mg
per kg. This represents mostly epidermal PpIX as seen on
¯uorescence micrographs. Although PpIX accumulation was not
detected for patients who received 5 mg per kg this may have been
due to the detection limit of our in vivo ¯uorescence spectrometer.
In addition the detection of PpIX levels after administration of low
dose ALA can be confounded by the presence of endogenous PpIX
in psoriatic scales (Bissonnette et al, 1998). In a previous study using
a different in vivo ¯uorescence spectrometer we were able to detect
Figure 6. Following oral administration of
ALA red ¯uorescence accumulates mostly in
the epidermis. Fluorescence micrographs
showing epidermal red ¯uorescence were
generated before (a), as well as 1 h (b), 3 h (c),
and 6 h (d) after ALA administration at 15 mg per
kg. Granular ¯uorescence was also present in the
dermis at 6 h. Corresponding sections were
stained with toluidine blue after ¯uorescence
microscopy (e, f, g, h).
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PpIX ¯uorescence in psoriatic skin of patients who received 20 and
30 mg per kg but not 10 mg per kg (Bissonnette and Haishan,
2001), which demonstrates the importance of instrumental sensi-
tivity. The absence of PpIX for patients who received 5 mg per kg
also does not necessarily indicate that blue light exposure after this
ALA dose would be ineffective, as in vivo ¯uorescence spectroscopy
predominantly measures PpIX accumulation within the epidermis.
If suf®cient PpIX is present in lesional T lymphocytes after
administration of ALA at 5 mg per kg to induce apoptosis upon
light exposure, it would be clinically desirable to use lower ALA
doses to avoid facial photosensitivity. The relatively low ¯uences
used with 5 mg per kg in this study may also explain the absence of
increased apoptosis levels for T lymphocytes.
Improvement in plaque severity was observed at the higher
¯uences for patients treated with 15 mg per kg. Although
encouraging, the presence of improvement cannot be interpreted
as de®nite proof of ef®cacy due to the limited number of patients
treated and the absence of a placebo-controlled group in this study.
In order to assess ef®cacy, further studies will need to be performed
comparing ALA±PDT to placebo. The presence of apoptosis in
lesional T lymphocytes after systemic ALA±PDT suggests that this
therapeutic modality could be useful for other diseases where T
lymphocyte activation plays a central role, such as atopic dermatitis
or alopecia areata. We have recently shown that ALA±PDT
induces apoptosis in malignant T cells in vitro (Gad et al, 2001). This
observation coupled with reports of improvement following topical
Figure 7. Epidermal levels of PpIX are increased after
administration of ALA at 10 mg per kg and 15 mg per kg. PpIX
levels were determined in the epidermis and stratum corneum with
quantitative ¯uorescence microscopy for patients who received ALA at
5 mg per kg, 10 mg per kg, and 15 mg per kg. Values represent average
pixel intensity in the stratum corneum or the rest of the epidermis. Bars:
SD; n = 16 sections from four patients for each dose and each time
point.
Figure 8. Presence of TUNEL+ CD3+ cells in the dermis after
ALA±PDT at 10 mg per kg. TUNEL-positive cells are indicated by
arrowheads (a) whereas CD3-positive lymphocytes on the same section are
indicated by arrows (b). Scale bar: 30 mm.
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ALA±PDT in patients with mycosis fungoides (Wolf et al, 1994)
also suggests that systemic ALA±PDT should be further explored
for this indication.
In conclusion this study showed that PDT with blue light
exposure after oral administration of ALA induces apoptosis in
lesional T lymphocytes. The clinical improvement observed at the
highest ALA doses and ¯uences suggests that this therapeutic
modality should be further investigated for the treatment of
psoriasis.
This study was supported by a grant from DUSA Pharmaceuticals. The authors
would like to thank Gilles Viau and Soraya Sharfaei for expert technical assistance
as well as Dr. Nik Kollias for helpful discussions on in vivo ¯uorescence
spectroscopy.
REFERENCES
Bissonnette R, Lui H: Current status of photodynamic therapy in dermatology.
Dermatol Clin 15:507±519, 1997
Bissonnette R, Zeng H, McLean DI, et al: Psoriatic plaques exhibit red
auto¯uorescence that is due to protoporphyrin IX. J Invest Dermatol
111:586±591, 1998
Bissonnette R, Haishan Z, McLean DI, et al: Oral aminolevulinic acid induces
protoporphyrin IX ¯uorescence in psoriatic plaques and peripheral blood cells.
Photochem Photobiol 74:339±345, 2001
Boehncke WH, Sterry W, Kaufmann R: Treatment of psoriasis by topical
photodynamic therapy with polychromatic light. Lancet 343:801, 1994
Coven TR, Walters IB, Cardinale I, et al: PUVA-induced lymphocyte apoptosis:
mechanism of action in psoriasis. Photodermatol Photoimmunol Photomed 15:22±
27, 1999
Gad F, Viau G, Boushira M, et al: Photodynamic therapy with 5-aminolevulinic acid
induces apoptosis and caspase activation in malignant T cells. J Cut Med Surg
5:8±13, 2001
Gottlieb AB: Immunopathogenesis of psoriasis. The road from bench to bedside is a
2-way street. Arch Dermatol 133:781±782, 1997
Gottlieb SL, Gilleaudeau P, Johnson R, et al: Response of psoriasis to a lymphocyte-
selective toxin (DAB389IL-2) suggests a primary immune, but not
keratinocyte, pathogenic basis. Nat Med 1:442±447, 1995
Kalka K, Merk H, Mukhtar H: Photodynamic therapy in dermatology. J Am Acad
Dermatol 42:389±413, 2000
Kennedy JC, Pottier RH: Endogenous protoporphyrin IX, a clinically useful
photosensitizer for photodynamic therapy. J Photochem Photobiol B 14:275±292,
1992
Koo J, Lebwohl M: Duration of remission of psoriasis therapy. J Am Acad Dermatol
41:51±59, 1999
Krueger JG, Wolfe JT, Nabeya RT, et al: Successful ultraviolet B treatment of
psoriasis is accompanied by a reversal of keratinocyte pathology and by selective
depletion of intraepidermal T cells. J Exp Med 182:2057±2068, 1995
Oh CJ, Das KM, Gottlieb AB: Treatment with anti-tumor necrosis factor alpha
(TNF-alpha) monoclonal antibody dramatically decreases the clinical activities
of psoriasis lesions. J Am Acad Dermatol 42:829±830, 2000
Regula J, MacRobert AJ, Gorchein A, et al: Photosensitisation and photodynamic
therapy of oesophageal, duodenal, and colorectal tumours using 5
aminolaevulinic acid induced protoporphyrin IX ± a pilot study. Gut 36:67±
75, 1995
Rick K, Sroka R, Stepp H, et al: Pharmacokinetics of 5-aminolevulinic acid-induced
protoporphyrin IX in skin and blood. J Photochem Photobiol B 40:313±319, 1997
Rittenhouse-Diakun K, Van Leengoed H, Morgan J, et al: The role of transferrin
receptor (CD71) in photodynamic therapy of activated and malignant
lymphocytes using the heme precursor delta-aminolevulinic acid (ALA).
Photochem Photobiol 61:523±528, 1995
Rizova H, Nicolas JF, Morel P, et al: The effect of anti-CD4 monoclonal antibody
treatment on immunopathological changes in psoriatic skin. J Dermatol Sci 7:1±
13, 1994
Robinson DJ, Collins P, Stringer MR, et al: Improved response of plaque psoriasis
after multiple treatments with topical 5-aminolaevulinic acid photodynamic
therapy. Acta Derm Venereol 79:451±455, 1999
Sibille A, Lambert R, Souquet JC, et al: Long-term survival after photodynamic
therapy for esophageal cancer. Gastroenterology 108:337±344, 1995
Webber J, Kessel D, Fromm D: Side effects and photosensitization of human tissues
after aminolevulinic acid. J Surg Res 68:31±37, 1997
Wolf P, Fink-Puches R, Cerroni L, et al: Photodynamic therapy for mycosis
fungoides after topical photosensitization with 5-aminolevulinic acid. J Am
Acad Dermatol 31:678±680, 1994
Wrone-Smith T, Mitra RS, Thompson CB, et al: Keratinocytes derived from
psoriatic plaques are resistant to apoptosis compared with normal skin. Am J
Pathol 151:1321±1329, 1997
Figure 9. The number of TUNEL+ CD3+ cells per ®eld is
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